Lindsey Ada M, Gross Gloria, Twiss Jan, Waltman Nancy, Ott Carol, Moore Timothy E
College of Nursing, University of Nebraska Medical Center, Omaha 68198-5330, USA.
Cancer Nurs. 2002 Feb;25(1):50-6. doi: 10.1097/00002820-200202000-00010.
Postmenopausal survivors of breast cancer for whom hormone replacement therapy is contraindicated are at risk for development of osteoporosis. The primary purpose of this article is to describe, in a sample of 30 postmenopausal survivors of breast cancer, their calcium and vitamin D intake compared with recommended dietary guidelines for those nutrients for postmenopausal women not taking hormone replacement therapy and the body mass index of these women as nutritional status risk factors for development of osteoporosis. Bone health and presence of osteoporosis were determined by bone mineral density testing of the spine, hip, and forearm. To obtain calcium and vitamin D intake, including supplements, 3-day diet records were completed; height and weight measures were used to calculate body mass index. The sample participants ranged in age from 42 to 65 years; the majority (56%) had been menopausal or off hormone replacement therapy for 5 years or less, and 70% had completed breast cancer treatment for 5 years or less (except tamoxifen). The majority (63%) were of medium body frame size; 30% were of small frame size. The mean body mass index (27.3) and mean weight (160 lbs) indicate that these women, as a group, were over-weight. Although a large percent (63%) were taking calcium supplements, the mean daily intake (diet and supplements) of calcium (1,353 mg) and vitamin D (403 IU) was less than the recommended dietary guidelines for these nutrients in this population. At study entry, 80% of the women were osteopenic (60%) or osteoporotic (20%) and none was receiving treatment/prevention for osteoporosis; only 1 had a previous known osteoporosis diagnosis. This is a special group of women for whom screening and preventive strategies for osteoporosis are imperative.
激素替代疗法禁忌的绝经后乳腺癌幸存者有患骨质疏松症的风险。本文的主要目的是在30名绝经后乳腺癌幸存者样本中，描述她们的钙和维生素D摄入量，并与未接受激素替代疗法的绝经后女性这些营养素的推荐饮食指南进行比较，同时描述这些女性的体重指数作为骨质疏松症发生的营养状况风险因素。通过对脊柱、髋部和前臂进行骨密度测试来确定骨骼健康状况和骨质疏松症的存在情况。为了获取钙和维生素D的摄入量（包括补充剂），完成了3天的饮食记录；使用身高和体重测量值来计算体重指数。样本参与者年龄在42岁至65岁之间；大多数（56%）处于绝经状态或停止激素替代疗法5年或更短时间，70%完成乳腺癌治疗5年或更短时间（他莫昔芬除外）。大多数（63%）为中等身材体型；30%为小身材体型。平均体重指数（27.3）和平均体重（160磅）表明，这些女性作为一个群体超重。尽管很大比例（63%）的女性正在服用钙补充剂，但钙（1353毫克）和维生素D（403国际单位）的平均每日摄入量（饮食和补充剂）低于该人群这些营养素的推荐饮食指南。在研究开始时，80%的女性患有骨质减少症（60%）或骨质疏松症（20%），且无人接受骨质疏松症的治疗/预防；只有1人之前有已知的骨质疏松症诊断。这是一组特殊的女性，对她们而言，骨质疏松症的筛查和预防策略至关重要。
